Rebeca Palafox‐Romo

Rebeca Palafox‐Romo

Auto-generated profile, based on publicly available information

Rebeca Palafox‐Romo

Dermatology Department National Institute of Medical Sciences and Nutrition Salvador Zubirán Mexico City Mexico

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in International Journal of Dermatology
Verified
Journal Article
Closed access
AMAndrea Malagón‐Liceaga
Andrea Malagón‐Liceaga
SBSamantha Paola Bermúdez‐Rodríguez
Samantha Paola Bermúdez‐Rodríguez
JRJesús Alejandro Romero‐Aguila
Jesús Alejandro Romero‐Aguila
LCLopez‐Jimenez Fanny Carolina
Lopez‐Jimenez Fanny Carolina
RPRebeca Palafox‐Romo
Rebeca Palafox‐Romo
ARAna Lilia Ruelas‐Villavicencio
Ana Lilia Ruelas‐Villavicencio

30 March 2025 in JEADV Clinical Practice
Verified
Journal Article
Open access
AMAndrea Malagon‐Liceaga
Andrea Malagon‐Liceaga
JRJesus Alejandro Romero‐Aguila
Jesus Alejandro Romero‐Aguila
BLBonfilio Roberto Lazcano‐Prieto
Bonfilio Roberto Lazcano‐Prieto
FLFanny Carolina Lopez‐Jimenez
Fanny Carolina Lopez‐Jimenez
RPRebeca Palafox‐Romo
Rebeca Palafox‐Romo
ARAna Lilia Ruelas‐Villavicencio
Ana Lilia Ruelas‐Villavicencio
Background: Cutaneous squamous cell carcinoma (cSCC) poses a high metastatic risk in immunosuppressed individuals, especially organ transplant recipients (OTRs). Despite international guidelines recognizing these risks, no universal standard exists for assessing quality of care (QoC) in cSCC. QoC indicators, as defined by NICE, ensure evidence‐based management, including histopathology, treatment timelines, and follow‐up, yet adherence remains challenging, particularly in low‐ and middle‐income countries.Objectives: To evaluate the occurrence of metastasis in cSCC among Mexican renal transplant recipients (RTRs) and assess how QoC indicators influenced this outcome.Methods: Analysis of a subgroup of patients with invasive cSCC from a cohort of 1642 RTRs, excluding keratoacanthomas, SCC in situ, and externally treated tumors, leaving 123 cases. QoC indicators included pathology report completeness, diagnosis‐to‐surgery time, follow‐up duration, and surgical team involvement. Comprehensive reports documented tumor size, depth, differentiation, and perivascular/perineural invasion. Statistical analysis included Fisher's exact test, Wilcoxon‐Mann‐Whitney test, and LASSO logistic regression.Results: Among the 123 tumors, 4.9% metastasized, 83.3% in men. Notably, 19.4% of tumors had a comprehensive pathology report. The AJCC 7 guidelines in 2015 improved reporting quality, with 30.5% of reports meeting comprehensive criteria post‐2015, compared to 9.4% before (p = 0.005). LASSO logistic regression identified predictors of metastasis: tumor differentiation (OR 3.0, 95%CI: 2–4.5), reporting tumor depth (OR 1.4, 95%CI: 1.2–1.7), and reporting perivascular invasion (OR 8.66, 95%CI: 4.8–15.6). This suggests that pathologists may have been more likely to document aggressive‐looking tumors. Time to surgery was similar across cases, but multidisciplinary teams were more involved in metastatic cases.Conclusions: The lack of universally recognized QoC guidelines for cSCC treatment in OTRs presents a significant gap in patient care. Standardized reporting and treatment protocols, similar to melanoma guidelines, could improve outcomes and support research like ours. The study's retrospective nature and missing data require cautious interpretation.

1 July 2024
Verified
Journal Article
Open access
SMSilvia Mendez-Flores
Silvia Mendez-Flores
RPRebeca Palafox-Romo
Rebeca Palafox-Romo
LELilly Esquivel-Pedraza
Lilly Esquivel-Pedraza
Generalized lupus erythematosus (LEG) is an autoimmune disease with cutaneous and mucosal manifestations, with lupus cheilitis (LC) being a rare associated oral presentation. The difficulty in early diagnosis of QL lies in its various clinical forms. Although successful treatments have been described, information on specific management is limited, highlighting the importance of early recognition to improve the prognosis and quality of life of patients. We describe the case of a 24-year-old woman with SLE of four years' duration, under treatment with prednisone. She presented a bilateral painful vermilion stomatosis, with extensive erosions and ulcerations covered by hematic crusts, showing no improvement despite previous topical treatments. Histopathological analysis revealed lymphoplasmacytic spongiotic stomatitis with eosinophils and lupus stomatitis associated with contact irritation. The dose of prednisone was adjusted, noting improvement after a month of treatment. Even though the oral mucosa is commonly affected in SLE, LC is uncommon. The clinical presentation of QL starts with macules on the lips, and eventually presents with edema and painful ulcers. The diagnosis is essentially clinical but challenging cases may require a pathology report. Management includes adjustment of corticosteroid doses and general measures; early diagnosis is crucial for an adequate treatment response.